艾迪注射液联合多西他赛、卡铂化疗方案对非小细胞肺癌的近期疗效  

Effective and Safety of Addie Injection and Docetaxel and Carboplatin Chemotherapy for Non-Small Cell Lung Cancer

作　　者：何志锋[1] 刘瑜[1] 吴原波[1] 

机构地区：[1]温州医科大学附属第一医院心胸外科,浙江温州325000

出　　处：《中华中医药学刊》2016年第6期1459-1461,共3页Chinese Archives of Traditional Chinese Medicine

基　　金：温州市科技局项目(Y20110258)

摘　　要：目的:观察并探讨艾迪注射液与多西他赛(Docetaxel,DCT)、卡铂(Carboplatin,CP)化疗方案联合治疗非小细胞肺癌(Non-small cell lung cancer,NSCLC)的近期疗效和安全性。方法:选择2010年4月—2014年3月期间接诊的NSCLC患者78例,按照随机数字法将78例患者分为两组,观察组和对照组各39例,对照组给予DCT+CP化疗方案,观察组在对照组的基础上给予艾迪注射液治疗。随访并评价两组实体肿瘤近期疗效,治疗前后生存质量评分及不良反应发生情况。结果:观察组缓解率(CR+PR)为35.9%(14/39),对照组为30.8%(12/39),观察组缓解率明显高于对照组(P<0.05);两组治疗前生存质量评分各项相比,差异不具有统计学意义(P>0.05);治疗后,观察组生理功能、情感功能、社会功能得分明显高于对照组(P<0.05),而疲劳、疼痛和呕吐得分明显更低(P<0.05);观察组消化道反应、白细胞减少和血小板减少发生率分别为30.8%(12/39)、12.8%(5/39)和10.2%(4/39),对照组为38.5%(15/39)、30.8%(12/39)和15.4%(6/39),观察组血小板减少发生率明显低于对照组(P<0.05)。结论:艾迪注射液联合DCT+CP化疗方案治疗NSCLC疗效显著,可提升患者生活质量,且具有更高的安全性。Objective： To observe and explore the effect of Addie Injection and Docetaxel（ DCT） and carboplatin（ CP） chemotherapy for non-small cell lung cancer（ NSCLC）. Methods： Seventy-eight NSCLC cases accepted treatment during April 2010 to March 2014 in this hospital were selected and divided into two groups according to the random number method,39 cases in each group. The control group was treated with DCT ＋ CP chemotherapy while the observation group treated with Addie Injection on the basis of control group. Primary efficacy of advanced solid tumor was evaluated.Quality of life score before and after treatment as well as the occurrence of adverse reactions were followed-up. Results：Remission rate（ CR ＋ PR） in observation group was 35. 9%（ 14 /39） while it was 30. 8%（ 12 /39） in the control group. The remission rate was significantly higher in the observation group than that in the control group（ P〈0. 05）.The difference of quality of life score was not statistically significant（ P〉0. 05） in the two groups before treatment. After treatment,physiological function,emotional function and social function scores in the observation group were significantly higher than those in the control group（ P〈0. 05）. Fatigue,pain and vomiting scores were significantly lower（ P〈0. 05）. Incidence rates of alimentary tract reactions,leukocyte reduction and platelet reduce were 30. 8%（ 12 /39）,12. 8%（ 5 /39） and 10. 2%（ 4 /39）,respectively and in the control group were 38. 5%（ 15 /39）,30. 8%（ 12 /39） and15. 4%（ 6 /39）. The incidence of platelet reduce in the observation group was significantly lower than those in the control group（ P〈0. 05）. Conclusion： Addie Injection combined with DCT ＋ CP chemotherapy has a significant effect on the treatment of NSCLC,which can improve the quality of life of patients and has higher safety.

关 键 词：艾迪注射液 化疗 非小细胞肺癌 近期疗效 

分 类 号：R734.2[医药卫生—肿瘤]